Express Pharma
Home  »  Latest Updates  »  Alembic Pharma gets USFDA nod for depressive disorder drug

Alembic Pharma gets USFDA nod for depressive disorder drug

26
Read Article

The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Wyeth Pharma Inc’s Pristiq tablets

Alembic Pharmaceuticals said recently it has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder.

The company has received approval from the USFDA to market its product which is a generic equivalent of Wyeth Pharma Inc’s Pristiq tablets, Alembic Pharmaceuticals said in a regulatory filing.

According to IQVIA, Desvenlafaxine extended-release tablets has a market size of around USD 13.3 million for twelve months ending December 2017.

Comments are closed.